Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anti-PD1/PDL1 Antibody”

85 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 85 results

Not applicableLooking for participantsNCT05713994
What this trial is testing

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma Non-resectable
Ze-yang Ding, MD 300
Early research (Phase 1)Study completedNCT01656642
What this trial is testing

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Genentech, Inc. 67
Large-scale testing (Phase 3)Study completedNCT03134872
What this trial is testing

SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC

Who this might be right for
Lung NeoplasmsCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+6 more
Jiangsu HengRui Medicine Co., Ltd. 419
Testing effectiveness (Phase 2)Looking for participantsNCT06827236
What this trial is testing

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

Who this might be right for
Locally Advanced Breast CancerUnresectable Breast CarcinomaMetastatic Breast Cancer
BioNTech SE 380
Not applicableLooking for participantsNCT07291063
What this trial is testing

Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA

Who this might be right for
Cholangiocarcinoma
Shanghai Zhongshan Hospital 50
Testing effectiveness (Phase 2)Study completedNCT04122625
What this trial is testing

Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143

Who this might be right for
Solid Tumor
Debiopharm International SA 46
Testing effectiveness (Phase 2)Active Not RecruitingNCT05287113
What this trial is testing

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Who this might be right for
Head and Neck Cancer
Incyte Biosciences International Sàrl 176
Testing effectiveness (Phase 2)Active Not RecruitingNCT04995523
What this trial is testing

AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

Who this might be right for
Non-Small-Cell Lung Carcinoma
AstraZeneca 212
Testing effectiveness (Phase 2)UnknownNCT05129189
What this trial is testing

Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide in HIV-infected Patients With Antiviral Suppression

Who this might be right for
HIV Infections
Shanghai Public Health Clinical Center 15
Large-scale testing (Phase 3)Study completedNCT04205812
What this trial is testing

Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer

Who this might be right for
Metastatic Squamous Non-Small Cell Lung CancerMetastatic Nonsquamous Non-Small Cell Lung Cancer
Incyte Corporation 583
Testing effectiveness (Phase 2)Study completedNCT04116073
What this trial is testing

INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer

Who this might be right for
Pancreatic Cancer Non-resectablePancreatic Cancer Metastatic
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 25
Testing effectiveness (Phase 2)WithdrawnNCT07038915
What this trial is testing

STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1

Who this might be right for
Lung Squamous Cell CarcinomaAnti-PD1/PDL1 Antibody
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT02628132
What this trial is testing

Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients

Who this might be right for
Breast Cancer
King Faisal Specialist Hospital & Research Center 22
Large-scale testing (Phase 3)UnknownNCT05661240
What this trial is testing

Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd 348
Early research (Phase 1)Ended earlyNCT04060342
What this trial is testing

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Who this might be right for
Pancreatic AdenocarcinomaEsophageal AdenocarcinomaEsophageal Squamous Cell Carcinoma+11 more
GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. 61
Testing effectiveness (Phase 2)UnknownNCT03085069
What this trial is testing

Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC

Who this might be right for
Lung NeoplasmsCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms Nec+4 more
Jiangsu HengRui Medicine Co., Ltd. 146
Testing effectiveness (Phase 2)Looking for participantsNCT04777084
What this trial is testing

The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.

Who this might be right for
Non-Small Cell Lung Cancer
Hunan Province Tumor Hospital 120
Not applicableUnknownNCT05701553
What this trial is testing

Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Shanghai Zhongshan Hospital 20
Testing effectiveness (Phase 2)Study completedNCT02694822
What this trial is testing

AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

Who this might be right for
Advanced Solid CancersAdvanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies
Agenus Inc. 89
Testing effectiveness (Phase 2)Active Not RecruitingNCT06631079
What this trial is testing

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors

Who this might be right for
Solid Tumor
NEC Bio B.V 20
Next Page